Li-Fraumeni Syndrome
Conditions
Interventions
LFS Cancer Surveillance Program
Sponsors
Japan Children's Cancer Group,(JCCG)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Following (1) through (6) . (1) Person who has diagnosed, suspected with Li-Fraumeni syndrome. A close relative of a person having TP53 pathogenic variant. (2) Age 39 years or younger (3) ECOG Performance Status (ECOG PS) of 0 to 2 (4) Person who have not yet developed cancer, or those who have already developed cancer but have been in remission for at least 1 year after completion of treatment. Treatment refers to surgical therapy, radiation therapy, chemotherapy (anti-cancer drugs), and molecular targeted therapy. (Hormone therapy is acceptable.) (5) Person who has received genetic counseling and consents to undergo TP53 genetic testing. (6) Person who have obtained written consent.
Exclusion criteria
Exclusion criteria: (1) Women who are pregnant or may become be pregnant. (2) Person with contraindications to MRI imaging (3) Person who require sedation for MRI imaging. (4) Those who are judged by the principal investigator or researcher to be inappropriate to participate in the research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| One-year continuity of the surveillance program | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy of Each examination in the Surveillance Program Necessity of the Cancer Surveillance Program Efficacy of the Cancer Surveillance Program Benefits and Disadvantages of the Surveillance as Perceived by Study Participants Problems in implementing the cancer surveillance programs and how to address them Assessing the safety of the Cancer surveillance | — |
Countries
Japan
Contacts
Public ContactFumito Yamazaki
Keio University School of Medicine Department of Pediatrics
Outcome results
None listed